Dimensional Fund Advisors LP Has $122,000 Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Dimensional Fund Advisors LP lifted its stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 91.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,793 shares of the company’s stock after buying an additional 10,869 shares during the period. Dimensional Fund Advisors LP’s holdings in Corvus Pharmaceuticals were worth $122,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of Corvus Pharmaceuticals by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 566,863 shares of the company’s stock valued at $3,034,000 after acquiring an additional 3,854 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Corvus Pharmaceuticals by 1.1% in the 4th quarter. Renaissance Technologies LLC now owns 390,688 shares of the company’s stock valued at $2,090,000 after buying an additional 4,100 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at $624,000. Raymond James Financial Inc. acquired a new position in Corvus Pharmaceuticals in the 4th quarter worth $583,000. Finally, Barclays PLC boosted its stake in Corvus Pharmaceuticals by 10,601,800.0% in the 4th quarter. Barclays PLC now owns 106,019 shares of the company’s stock worth $567,000 after purchasing an additional 106,018 shares during the period. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Up 0.8%

CRVS stock opened at $3.61 on Friday. The firm has a market cap of $246.09 million, a PE ratio of -3.88 and a beta of 0.67. The business has a 50 day moving average of $3.56 and a 200-day moving average of $5.31. Corvus Pharmaceuticals, Inc. has a 12-month low of $1.75 and a 12-month high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). On average, research analysts expect that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRVS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. Oppenheimer reiterated an “outperform” rating and set a $17.00 target price (up previously from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. Finally, StockNews.com upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 12th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Corvus Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $16.33.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.